Cilacar T (Cilnidipine/Telmisartan)

Product Overview

Cilacar T is a prescription medication formulated to manage hypertension, commonly known as high blood pressure. It combines two active pharmaceutical ingredients, Cilnidipine and Telmisartan, in a fixed‑dose combination that targets different physiological pathways to achieve optimal blood pressure control. The product is manufactured by J. B. Chemicals and Pharmaceuticals Ltd, a company with a longstanding reputation in the Indian pharmaceutical market. Each strip contains ten tablets, each delivering a strength of 10 mg Cilnidipine and 40 mg Telmisartan. Pack sizes of 112, 56, and 28 tablets are available to suit varying treatment durations. This medication is intended for adult patients who require dual therapy to achieve their blood pressure goals.

What is Cilacar T

Cilacar T belongs to a class of antihypertensive agents that work through complementary mechanisms. Cilnidipine is a dihydropyridine calcium channel blocker that relaxes vascular smooth muscle, thereby reducing peripheral resistance. Telmisartan is an angiotensin II receptor blocker that inhibits the vasoconstrictive effects of angiotensin II, leading to vasodilation and improved renal perfusion. The combination provides a synergistic effect, allowing lower doses of each component to be used, which may minimize individual side effect profiles while maintaining therapeutic efficacy. The fixed‑dose format simplifies dosing regimens and improves patient adherence.

Uses and Benefits

The primary indication for Cilacar T is the treatment of essential hypertension in adults. By effectively lowering systolic and diastolic blood pressure, the medication reduces the risk of cardiovascular complications such as myocardial infarction, cerebrovascular accident, and chronic kidney disease. Clinical studies have demonstrated that the dual‑action approach can achieve target blood pressure levels in a higher proportion of patients compared with monotherapy. Additionally, the fixed‑dose combination may improve medication adherence, which is a critical factor in long‑term blood pressure control. Patients often report fewer missed doses and a lower incidence of breakthrough hypertension episodes when using this formulation.

How It Works

Cilnidipine exerts its antihypertensive effect by blocking L‑type calcium channels on vascular smooth muscle cells. This blockade prevents the influx of calcium ions, leading to relaxation of arterial walls and a consequent decrease in systemic vascular resistance. Telmisartan, on the other hand, selectively blocks the AT1 receptor subtype of angiotensin II, a potent vasoconstrictor. Inhibition of this receptor attenuates vasoconstriction, reduces aldosterone secretion, and improves renal blood flow. The combined action results in a more pronounced and sustained reduction in blood pressure, often with a lower incidence of reflex tachycardia compared with some other antihypertensive classes.

Dosage Guidelines

The recommended initial dosage of Cilacar T is one tablet taken orally once daily, preferably with or without food. The tablet should be swallowed whole and not crushed or chewed. Depending on the patient’s response and tolerability, healthcare providers may adjust the dose upward, but the maximum recommended daily dose remains the fixed combination strength of 10 mg Cilnidipine and 40 mg Telmisartan per tablet. For patients with renal impairment, dose modification may be necessary, and periodic monitoring of serum creatinine is advised. It is essential to follow the prescribing clinician’s instructions precisely and to avoid self‑adjustment of the dose without medical supervision.

Side Effects

Like all medicinal products, Cilacar T can be associated with adverse effects, although not every user experiences them. Commonly reported side effects include dizziness, headache, peripheral edema, and mild gastrointestinal discomfort. Less frequent but clinically important events may involve hyperkalemia, renal function impairment, or changes in liver enzyme levels. Rarely, patients may experience allergic skin reactions or hypotension accompanied by fainting. If any of these symptoms persist or worsen, the medication should be discontinued and a healthcare professional contacted promptly. Patients are encouraged to report any unexpected reactions to their physician or local pharmacovigilance authority.

Warnings and Precautions

Cilacar T is contraindicated in individuals with known hypersensitivity to either Cilnidipine or Telmisartan, as well as in patients with severe hepatic impairment. The drug should be used with caution in those with a history of angioedema related to angiotensin receptor blockade. Pregnant women should avoid its use, particularly during the second and third trimesters, as Telmisartan may cause fetal toxicity. Breastfeeding mothers are advised to consult a physician before initiating therapy, as the extent of excretion in milk is not fully established. Concomitant use of potassium‑sparing agents or other medications that affect renal perfusion may require dose adjustments and close laboratory monitoring.

Frequently Asked Questions

Q1: What is the difference between Cilnidipine and Telmisartan?
A: Cilnidipine is a calcium‑channel blocker that works by relaxing the muscles in the walls of blood vessels, which lowers peripheral resistance. Telmisartan is an angiotensin‑II receptor antagonist that blocks the action of a hormone that causes blood vessels to tighten. Together they target two distinct pathways, allowing each drug to be used at a lower dose while still achieving strong blood‑pressure control. For a detailed comparison, see the NIH’s hypertension resources: NIH.

Q2: Can Cilacar T be taken with other blood pressure medications?
A: Cilacar T is formulated as a fixed‑dose combination, meaning it already contains two active antihypertensive agents. Adding other blood‑pressure drugs, such as diuretics, beta‑blockers, or additional calcium‑channel blockers, can increase the likelihood of excessive blood‑pressure lowering and may cause dizziness or fainting. Before combining therapies, discuss the regimen with a qualified healthcare professional. The U.S. Food and Drug Administration provides guidance on drug interactions: FDA Interaction Checker.

Q3: How long does it take to see a reduction in blood pressure?
A: Most patients experience a modest reduction in systolic and diastolic pressure within a few hours after the first dose of Cilacar T, but the full therapeutic effect is usually observed after several days of consistent use. Blood‑pressure goals are typically reached after one to two weeks, provided the medication is taken exactly as prescribed. Regular monitoring by a clinician helps determine whether the current dose is adequate or if adjustments are needed. Individual response can vary based on factors such as age, kidney function, and concomitant lifestyle changes.

Q4: Is it safe for elderly patients?
A: Elderly individuals often have reduced kidney function, which can affect how the body eliminates Cilacar T. Because of this, clinicians may start with a lower dose and monitor serum creatinine and electrolyte levels more frequently. Clinical trials have shown that the combination is generally well tolerated in older adults when dose adjustments are made appropriately. Nevertheless, close medical supervision is essential to avoid hypotension and to ensure that blood‑pressure targets are achieved safely. For evidence‑based guidance, refer to the NIH’s geriatric hypertension recommendations: NIH Geriatrics.

Q5: Where can I find more information about hypertension management?
A: Comprehensive information about hypertension, including lifestyle modifications, dietary recommendations, and self‑monitoring techniques, is available from reputable public health sources. The U.S. National Library of Medicine’s MedlinePlus portal offers up‑to‑date articles on hypertension treatment, medication safety, and when to seek medical attention. Visit the MedlinePlus hypertension page for reliable, consumer‑friendly resources: MedlinePlus Hypertension.

Related Products

• Cilnidipine 5 mg (Generic)
• Nicardia XL 30 Mg (Nifedipine)
• Cilacar (Cilnidipine)
• Cilacar 5 mg (Cilnidipine)
• Cilacar 10mg (Cilnidipine)
• Cilacar 20mg (Cilnidipine)
• Arkamin 100 (Clonidine)
• Abel 40 mg (Azilsartan Medoxomil)
• Metrogyl Gel (Metronidazole)
• Metrogyl Tablet (Metronidazole)
• Metrogyl 200mg (Metronidazole)
• Metrogyl 400mg (Metronidazole)